Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies

Front Matter....Pages I-XXIV
Front Matter....Pages 1-1
The New WHO Classification for Akute Myeloid Leukemias and Myelodysplastic Syndromes....Pages 3-6
How Representative is the GMALL of the German Population?....Pages 7-9
Philadelphia Chromosome-Positive Mature B-cell (Burkitt cell) Leukemia....Pages 10-11
8-Year’s Experience of Ukrainian Reference Laboratory for Diagnosis of Acute Leukemias in Children....Pages 12-14
Establishment of the B-Cell Precursor-Acute Lymphoblastic Leukemia Cell Line MUTZ-5 Carrying a (12;13) Translocation....Pages 15-18
Front Matter....Pages 19-19
The t(8;21), t(12;21), and inv(16) fusion Proteins Contact Co-Repressors and Histone Deacetylase to Repress Transcription....Pages 21-24
Disturbed Differentiation of AMLl/ETO Transduced Human CD34+ Progenitors....Pages 25-27
Inducible AML1/ET0 Expression in U-937 Myeloid Cells: a Model to Identify Genes Targeted by the Leukemia-Specific Fusion Protein....Pages 28-33
Mix and Match Gene Fusions with TEL and AMLl....Pages 34-39
Transcriptional Repression of C/EBPα by Histone Deacetylases in Acute Myeloid Leukemia....Pages 40-43
Biology of Transcription Factor GATA-2 in Normal and Leukaemic Haematopoiesis....Pages 44-51
Retinoic Acid in Myeloid Differentiation and Acute Promyelocytic Leukemia (APL)....Pages 52-61
Combined Arsenic Trioxide and GM-CSF Induces Differentiation in Retinoic Acid (RA)-Sensitive as well as -Resistant APL Cells by Modulating Jak2 Kinase....Pages 62-66
Different Mechanisms Lead to Rearrangements of the MLL Gene in Cases with Acute Myeloid Leukemia (AML) and Translocation t(10;l1)....Pages 67-71
Genes Specifically Expressed in Monocytic AML Cells Identified by Array Technology....Pages 72-76
Oncogenic Activation of Growth Factor Signals in AML....Pages 77-83
Establishment of Inducible Expression Systems to Study the Role of STAT-Transcription Factors in AML....Pages 84-89
Farnesyltransferase Inhibitors in Leukemia....Pages 90-96
Therapeutic Strategies that Overcome Resistance to Nucleoside Analogues: Dysregulating Checkpoint Response and Survival Pathways by UCN-01....Pages 97-108
Imatinib (STI571) for the Treatment of Chronic Myelogenous Leukemia (CML)....Pages 109-116
Front Matter....Pages 117-117
The Stem Cell Leukaemia Gene: A Critical Regulator of Haemopoiesis Vasculogenesis....Pages 119-121
Establishment of the Two Cytokine-Dependent Acute Myeloid Leukemia-Derived Cell Lines MUTZ-8 and MUTZ-11....Pages 122-127
Leukemia Stem Cells with Efficient Drug Efflux in Acute Myeloid Leukemia....Pages 128-135
Growth of Leukemic Progenitor Cells of Acute Lymphoblastic Leukemia in Co-Culture with Murine Stromal Cell Line MS-5....Pages 136-139
Reduced Level of Philadelphia Chromosome Positive (Ph+) Cells in Lineage Negative Side Population Bone Marrow Progenitor Cells from Patients with Chronic Myeloid Leukemia (CML)....Pages 140-149
Front Matter....Pages 151-151
New Developmental Agents and Directions in the Treatment of Acute Myelogenous Leukemia....Pages 153-160
Investigational Therapy in Acute Myeloid Leukemia: 2001....Pages 161-164
CMA-676: Mechanism of Action and Clinical Results....Pages 165-168
Mylotarg Therapy in Acute Myeloid Leukemia: Mechanism of Action and Implications for Future Treatment Protocols....Pages 169-176
Antibody-Based Therapy of Myeloid Leukemia....Pages 177-185
Anti-angiogenic Therapy in Acute Myeloid Leukemia....Pages 186-192
8-Chloro-cAMP Serves as a Prodrug for the RNA Directed Nucleoside Analog, 8-Chloro-Adenosine....Pages 193-199
Pharmacokinetics and Pharmacodynamics of Daunoxome in Acute Myeloid Leukemia Patients....Pages 200-202
Front Matter....Pages 203-203
Modulation of Multidrug Resistance in Acute Myeloid Leukemia....Pages 205-212
Proliferative Activity of Leukemic Blasts and Cytosine Arabinoside Pharmacodynamics are Associated with Cytogenetically Defined Prognostic Subgroups in Acute Myeloid Leukemia....Pages 213-219
No Evidence of MDR1 Gene Related Clonal Selection in Relapsed or Refractory Acute Myeloid Leukemia (AML)....Pages 220-231
The Role of Mutations in the Deoxycytidine Kinase (dCK) Gene in the Development of Acute Myeloid Leukemia (AML) Towards Relapsed and/or Refractory Disease....Pages 232-238
Quantitative Determination of Bcl-2 Expression in AML Cell Lines and in Normal and Leukemic Progenitor Cell Compartments by Laser Scanning Cytometry: Comparison with Flow Cytometry and Western Blot....Pages 239-251
Apoptosis of Peripheral Blood Leukocytes in Children Survived from Acute Lymphoblastic Leukemia....Pages 252-258
In Vitro Sensitivity to Chemotherapy-Induced Apoptosis in CD2 +ve and CD2 -ve Childhood T-All....Pages 259-262
Front Matter....Pages 203-203
A Systematic Approach to the Dissection of Apoptotic Blockades in Treatment-Refractory Acute Myeloid Leukemias....Pages 263-266
GM-CSF is the Mediator of the Proliferative Effect of Tumor Necrosis Factor Alpha in Acute Myeloid Leukemia-Derived Cell Lines....Pages 267-272
Acute Myeloid Leukemias Differ at Primary Diagnosis and Relapse in Endogenous Proliferative Activity, Response to Stimulation by Exogenous G-CSF and GM-CSF and Production of G-CSF....Pages 273-276
Etoposide Induces Transition of 14-3-3 from the Cytoplasma into the Nucleus where it Binds to Topoisomerase II....Pages 277-281
The CCC-assay: A new Assay for Characterization of Leukaemic Cells Surviving Chemotherapy in-vitro....Pages 282-286
Resistance to Drug-Induced Cytotoxicity in Acute Myeloid Leukemia is Significantly Correlated Between Inhibitors of Topoisomerases I and II and Nucleoside Analogues....Pages 287-290
Age-Related Differences in Cellular Drug Resistance in Children with Acute Myeloid Leukemia (AML)....Pages 291-298
Front Matter....Pages 299-299
FLT3 Length Mutations and MLL-Duplications in AML: Correlation to Cytogenetics, FAB-Subtype,and Prognosis....Pages 301-305
Identification of Partial Tandem Duplications of the MLL Gene in Acute Myeloid Leukemia: Prospective Analysis within the Multicenter Treatment Trial AML HD98-A....Pages 306-311
Single-Center Retrospective Analysis of Prognosis of 138 Patients Older than 55 Years with Acute Myeloid Leukemia....Pages 312-320
Acute Myeloid Leukemia in Elderly Patients: Prognostic Value of Bone Marrow Aspirate on 14 th Day of Induction Treatment....Pages 321-326
Simultaneous Monitoring of Minimal Residual Disease by RT-PCR of PML/RARα and RARα/PML Fusion Transcripts in Acute Promyelocytic Leukemia (APL)....Pages 327-331
Cytogenetic Studies and Cell Cycle Parameters in Acute Lymphoblastic Leukemia (ALL) in Children....Pages 332-337
Reliability of BCR-ABL RT-PCR in Adult Acute B-Lineage Lymphoblastic Leukemia: Results of Confirmational PCR....Pages 338-341
Evaluation of Minimal Residual Disease (MRD) in Children with T-Lineage Acute Lymphoblastic Leukemia....Pages 342-345
Evaluation of Minimal Residual Disease (MRD) in Children with B-Cell Acute Lymphoblastic Leukemia During Maintenance of Remission....Pages 346-349
Frequency of Cytogenetic Aberrations and their Influence on Results of Treatment in Childhood Acute Lymphoblastic Leukemia (ALL)....Pages 350-354
Evaluation of Minimal Residual Disease (MRD) in Children with B-Cell Acute Lymphoblastic Leukemia after Completion of Induction Therapy....Pages 355-358
Evaluation of Minimal Residual Disease....Pages 359-360
Front Matter....Pages 361-361
Biology Based Treatment Strategies for Acute Myeloid Leukemia....Pages 363-365
Front Matter....Pages 361-361
Cytogenetics for Treatment Stratification in De Novo Adult Acute Myeloid Leukemia....Pages 366-376
Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach....Pages 377-380
Therapy of Newly Diagnosed Acute Promyelocytic Leukemia. Results of the AMLCG....Pages 381-384
FS-HAI for Relapsed AML....Pages 385-393
Treatment of AML and High Risk MDS at M.D. Anderson: The Lone Star Approach....Pages 394-403
Long Remissions After Late Relapse of Acute Myeloid Leukaemia (AML) with Idarubicin + Cytarabine Conventional Doses Treatment....Pages 404-406
Outcome of Patients with Refractory/Recurrent Acute Myelogenous Leukaemia (AML) Treated at a Single Centre....Pages 407-411
Phase I Clinical Evaluation of Topotecan Combined with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia....Pages 412-417
7+3+VP-16 as Remission Induction / Consolidation and Two Types of Maintenance in Adult AML: 8 Years Results of Russian Multicenter Trial....Pages 418-422
Interferon-α plus ATRA Maintenance in High Risk AML....Pages 423-425
Weekly Oral Idarubicin: An Ambulatory Treatment of Acute Myeloid Leukemia in Poor-Risk Elderly Patients....Pages 426-430
Treatment of Relapsed AML of Childhood with Daunoxome-FLAG (Liposomal Daunorubicin, Fludarabine, High-Dose Cytarabine and G-CSF)....Pages 431-437
Front Matter....Pages 439-439
ALL HRG -Experience with Modified New York Regimen....Pages 441-444
Prospective, Multicenter Study of CNS-Toxicity and Health-Related Quality of Life in ALL-Patients....Pages 445-450
Limited Success with a Postremission Strategy Comprising Conventional Consolidation and High-Dose Treatment (HDT) with Autologous Peripheral Progenitor Cell (PBPC) Support for Adult Acute Lymphoblastic Leukaemia (ALL)....Pages 451-455
Single High-Dose Idarubicin in Advanced Acute Lymphoblastic Leukaemia: Clinical and Pharmacokinetics Results....Pages 456-460
Salvage Therapy for Resistant or Relapsing Acute Lymphoblastic Leukemia (ALL) after Idarubicin-Based Induction....Pages 461-464
Front Matter....Pages 467-467
Transplantation Strategies for High Risk Acute Myeloid Leukemias....Pages 469-472
Current Role of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation in Patients with AML....Pages 473-478
Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen....Pages 479-482
Front Matter....Pages 467-467
Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia....Pages 483-484
Adoptive Immunotherapy in Chimeras — Donor Lymphocyte Transfusions for the Treatment of Acute Myeloid Leukemia....Pages 485-490
Herpes Simplex Virus Thymidine Kinase-Transduced Human T Lymphocytes....Pages 491-496
Interferon Alpha and Gamma Differentially Alter the Susceptibility of Tumor Cells to Lysis by MHC-Restricted and Non-MHC-Restricted Cytotoxic Effector Cells....Pages 497-503
Targeting Acute Leukemia and Cancer by High-Affinity T-Cell-Receptor Transfer....Pages 504-507
Nonmyeloablative Conditioning Regimen in Patients with High Risk Acute Myeloid Leukemia: Unrelated and Sibling Allogeneic Hematopoietic Stem Cell Transplantation....Pages 508-513
Induction of Mixed Chimerism in Patients After Non-Myeloablative Stem Cell Transplantation (SCT) for High Risk Haematological Malignancies....Pages 514-519
Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) Immediately After Intensive Cytoreduction for High-Risk Myeloid Leukemias....Pages 520-524
Allogeneic Stem Cell Transplantation (HSCT) for Secondary Acute Leukemia Following MDS....Pages 525-529
Biology of Stem Cell Mobilization Induced by Cytokines....Pages 530-532
Feasibility of High Dose Melphalan (140 mg/m 2 ) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission....Pages 533-537
Front Matter....Pages 539-539
Strategies for Empiric Antifungal Therapy in Neutropenic Patients....Pages 541-546
Acute Leukemias: Management of Infections....Pages 547-553
Leukopenia is no Risk Factor for Phlebitis Associated with Peripheral Teflon Catheters....Pages 554-559
PCR-Mediated Detection of Aspergillus Species in Bronchoalveolar Lavage Samples of Febrile Neutropenic Patients with Acute Leukemias: Clinical Results....Pages 560-563
Interleukin-8, Interleukin-6 and C-Reactive Protein Serum Concentrations in Acute Leukemia Patients without and with Clinical Symptoms of Infection....Pages 564-568
Front Matter....Pages 569-569
Update on Antiemetic Strategies....Pages 571-577
Quality of Life and Coping in Patients with Acute Myeloid Leukemia (AML)....Pages 578-584
Helping Patients Deal with Sexual Difficulties During and after Cancer Treatment....Pages 585-589
Sperm Quality May be Impaired in Long-Term Acute Myeloid Leukemia Survivors after Chemotherapy....Pages 590-592
Back Matter....Pages 593-597